Yanling Zhou
Psychiatrist / clinician-researcher at the Affiliated Brain Hospital of Guangzhou Medical University
Data updated
Papers
Trials
Research Footprint
Yanling Zhou appears in 13 tracked papers (2018–2024), most studied alongside Ketamine, Esketamine and Psilocybin, across Depressive Disorders, Major Depressive Disorder (MDD) and Suicidality.
Most-cited paper: Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression (179 citations).
Frequent co-authors: Chengyu Wang, Yuping Ning and Wei Zheng.
Background & Research
Yanling Zhou is a psychiatrist and clinical researcher associated with the Affiliated Brain Hospital of Guangzhou Medical University in Guangzhou, China. Her work has focused on repeated ketamine and esketamine treatment for depression, suicidal ideation, anhedonia, cognition, and related biomarkers. She appears as an author on multiple trials and analyses in ketamine-responsive mood disorders.
Key Impact
She is a frequent author on clinical ketamine and esketamine studies in depression and suicidality, contributing to psychedelic-adjacent translational research on rapid-acting antidepressants.
Collaboration Network
10 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Yanling Zhou is associated with.